Abstract:
ObjectiveTo analyze the effects of butylphthalide combined with different doses of atorvastatin on the hemodynamics, oxygen metabolism, inflammation and coagulation factors in ischemic cerebrovascular disease(ICVD) patients treated with arterial intervention, and provide a reference basis for selecting atorvastatin dose.
MethodsOne hundred and eighty patients with ICVD were randomly divided into the high-dose group, low-dose group and control group(60 cases each group).Three groups were treated with arterial intervention combined with butylphthalide capsule by oral, and the high-dose and low-dose groups were additionally treated with 20 mg and 10 mg atorvastatin by oral, once a day, respectively.The changes of hemodynamics, oxygen metabolism, inflammation and coagulation factors among three groups were compared, and the recurrence of ICVD among three groups were compared after 9 months of treatment.
ResultsCompared with after 2 days of operation, the hemodynamics, oxygen metabolism, inflammation and coagulation factors in three groups were improved in varying degrees(P < 0.05 to P < 0.01), the above indictors in high-dose group were better than those in low-dose group and control group(P < 0.05 to P < 0.01), and which in low-dose group was better than that in control group after 14 days of operation(P < 0.01).There was no statistical significance in the incidence of adverse reactions among three groups(P>0.05).After 9 months of following up, the recurrence rate of ICVD in high-dose group was higher than that in low-dose group and control group(P < 0.05 and P < 0.01), and the difference in the recurrence rate of ICVD between low-dose group and control group was not statistically significant(P>0.05).
ConclusionsThe combination of butylphthalide with atorvastatin has positive effects on the improvement of hemodynamics, oxygen metabolism, inflammation, coagulation factors of ICVD patients after arterial intervention.Long-term oral administration of 20 mg atorvastatin can achieve more ideal improvement effects on the premise of ensuring safety, and further reduce the risk of ICVD recurrence.